Catalent confirmed plans to close its cell therapy site in Gosselies, Belgium, attributing the decision to changing market dynamics and customer needs. The company is considering transitioning work and capacity as it realigns its global CDMO footprint amid variable demand in cell and gene therapy manufacturing. The announcement follows broader industry pressure on manufacturing economics, capacity planning and client consolidation, and highlights the operational challenges CDMOs face balancing specialized facilities with shifting client pipelines.